CO6311066A2 - Composiciones de alta densidad que contienen posaconazol y formulaciones que comprenden las mismas - Google Patents

Composiciones de alta densidad que contienen posaconazol y formulaciones que comprenden las mismas

Info

Publication number
CO6311066A2
CO6311066A2 CO10141841A CO10141841A CO6311066A2 CO 6311066 A2 CO6311066 A2 CO 6311066A2 CO 10141841 A CO10141841 A CO 10141841A CO 10141841 A CO10141841 A CO 10141841A CO 6311066 A2 CO6311066 A2 CO 6311066A2
Authority
CO
Colombia
Prior art keywords
posaconazole
formulation
oral administration
provides
patients
Prior art date
Application number
CO10141841A
Other languages
English (en)
Spanish (es)
Inventor
Larry Fang
David Harris
Gopal Krishna
Allen Moton
Russel Prestipino
Marc Steinman
Jiansheng Wan
Hetty Waskin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41199703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6311066(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO6311066A2 publication Critical patent/CO6311066A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO10141841A 2008-04-15 2010-11-11 Composiciones de alta densidad que contienen posaconazol y formulaciones que comprenden las mismas CO6311066A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4517708P 2008-04-15 2008-04-15
US16648709P 2009-04-03 2009-04-03

Publications (1)

Publication Number Publication Date
CO6311066A2 true CO6311066A2 (es) 2011-08-22

Family

ID=41199703

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10141841A CO6311066A2 (es) 2008-04-15 2010-11-11 Composiciones de alta densidad que contienen posaconazol y formulaciones que comprenden las mismas

Country Status (19)

Country Link
US (2) US20110123627A1 (cg-RX-API-DMAC7.html)
EP (1) EP2285351A2 (cg-RX-API-DMAC7.html)
JP (3) JP2011516612A (cg-RX-API-DMAC7.html)
KR (1) KR20110004852A (cg-RX-API-DMAC7.html)
CN (2) CN102065842A (cg-RX-API-DMAC7.html)
AR (1) AR072858A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009236289B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0910627A2 (cg-RX-API-DMAC7.html)
CA (1) CA2720849A1 (cg-RX-API-DMAC7.html)
CL (1) CL2009000902A1 (cg-RX-API-DMAC7.html)
CO (1) CO6311066A2 (cg-RX-API-DMAC7.html)
MX (1) MX2010011295A (cg-RX-API-DMAC7.html)
NZ (1) NZ588460A (cg-RX-API-DMAC7.html)
PE (1) PE20091778A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015500492A1 (cg-RX-API-DMAC7.html)
SG (1) SG10201403986UA (cg-RX-API-DMAC7.html)
TW (1) TWI388324B (cg-RX-API-DMAC7.html)
WO (1) WO2009129300A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007370B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278957A2 (en) * 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
EP2540318B1 (en) 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
CN105283203B (zh) * 2013-06-03 2018-12-28 信越化学工业株式会社 用于热熔挤出的组合物以及通过使用该组合物制备热熔挤出物的方法
EP2837391B1 (en) * 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
CN104510707A (zh) * 2013-09-26 2015-04-15 博瑞生物医药技术(苏州)有限公司 一种泊沙康唑固体分散体及其制备方法
CN104546667A (zh) * 2013-10-22 2015-04-29 博瑞生物医药技术(苏州)有限公司 含泊沙康唑的固体分散体及其制备方法
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
US10117836B2 (en) 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
CN110179801B (zh) * 2014-04-11 2021-08-06 上海宣泰医药科技股份有限公司 泊沙康唑药物组合物及其制备方法和药物制剂
US11058682B2 (en) * 2015-08-08 2021-07-13 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant formulation containing posaconazole
EP3925601B1 (en) 2016-02-26 2024-07-17 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor
WO2017032908A1 (en) 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
CN106265526A (zh) * 2016-09-22 2017-01-04 山东大学 一种抗真菌药物泊沙康唑的固体分散体及制备方法与应用
TR201620462A2 (tr) 2016-12-31 2018-07-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
US20180282527A1 (en) * 2017-03-30 2018-10-04 Shin-Etsu Chemical Co., Ltd. Injection molding composition containing hypromellose acetate succinate and method for producing same
US10702520B1 (en) 2019-01-29 2020-07-07 Slayback Pharma Llc Pharmaceutical compositions of posaconazole
US20230149452A1 (en) * 2020-04-06 2023-05-18 Yogesh BENDALE Structurally defined, better tolerated, orally adminstered, processed arsenolite, a process for its preparation, a pharmaceutical composition and uses thereof
EP4196096A1 (en) 2020-08-13 2023-06-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant high-strength formulation containing posaconazole
CN112697937A (zh) * 2020-12-18 2021-04-23 卓和药业集团有限公司 泊沙康唑肠溶片溶出度的分析方法
WO2023012378A1 (en) 2021-11-25 2023-02-09 Alfred E. Tiefenbacher (Gmbh Und Co. Kg) Granules containing posaconazole
EP4091604B1 (en) 2021-11-25 2024-04-03 Alfred E. Tiefenbacher (GmbH & Co. KG) Granules containing posaconazole
CN114184721A (zh) * 2021-12-14 2022-03-15 江苏恒盛药业有限公司 泊沙康唑残留溶剂的检测方法
CN115721601A (zh) * 2022-11-23 2023-03-03 无锡福祈制药有限公司 一种泊沙康唑纳米晶口服固体药物组合物及其制备方法
CN117545470A (zh) * 2023-09-18 2024-02-09 北京德立福瑞医药科技有限公司 泊沙康唑固体分散体及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
US5703079A (en) * 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
NZ270418A (en) * 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
US6509038B2 (en) * 1996-05-20 2003-01-21 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
JP5159012B2 (ja) * 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
PL212985B1 (pl) * 2001-04-03 2012-12-31 Schering Corp Ciekla zawiesina zawierajaca przeciwgrzybiczo skuteczna ilosc posakonazolu oraz zastosowanie zmikronizowanych czastek posakonazolu
JPWO2003077827A1 (ja) * 2002-03-19 2005-07-14 日本新薬株式会社 医薬固体分散体の製造方法
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
WO2006034080A2 (en) * 2004-09-17 2006-03-30 Nektar Therapeutics Formulation comprising itraconazole
US20060275230A1 (en) * 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
CN101495096A (zh) * 2006-05-30 2009-07-29 伊兰制药国际有限公司 纳米微粒泊沙康唑制剂
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ.ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
EP2278957A2 (en) * 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas

Also Published As

Publication number Publication date
MX2010011295A (es) 2010-11-12
NZ588460A (en) 2012-07-27
KR20110004852A (ko) 2011-01-14
CN104983701A (zh) 2015-10-21
JP2014139230A (ja) 2014-07-31
CN102065842A (zh) 2011-05-18
PH12015500492A1 (en) 2017-04-10
EP2285351A2 (en) 2011-02-23
ZA201007370B (en) 2011-06-29
CA2720849A1 (en) 2009-10-22
WO2009129300A2 (en) 2009-10-22
US20150150990A1 (en) 2015-06-04
TWI388324B (zh) 2013-03-11
AU2009236289B2 (en) 2014-08-21
WO2009129300A3 (en) 2010-02-11
BRPI0910627A2 (pt) 2015-09-22
TW200946121A (en) 2009-11-16
AU2009236289A1 (en) 2009-10-22
JP2011516612A (ja) 2011-05-26
SG10201403986UA (en) 2014-10-30
US20110123627A1 (en) 2011-05-26
JP2016074698A (ja) 2016-05-12
PE20091778A1 (es) 2009-11-13
AR072858A1 (es) 2010-09-29
CL2009000902A1 (es) 2010-07-23

Similar Documents

Publication Publication Date Title
ES2557475T3 (es) Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones
ES2938560T3 (es) Formulaciones de cannabinoides estables
ES2753198T3 (es) Formas farmacéuticas orales de liberación controlada de fármacos poco solubles y sus usos
ES2830447T3 (es) Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación
ES2899226T3 (es) Composiciones liofilizadas en superficie específica elevada que comprende el arsénico destinadas a una administración oral en pacientes
CY1116874T1 (el) Δοσολογικο σχημα για τη χορηγηση ενος cd19xcd3 αμφιειδικου αντισωματος
JP2019519581A (ja) 2−[3−[4−アミノ−3−(2−フルオロ−4−フェノキシ−フェニル)ピラゾロ[3,4−d]ピリミジン−1−イル]ピペリジン−1−カルボニル]−4−メチル−4−[4−(オキセタン−3−イル)ピペラジン−1−イル]ペント−2−エネニトリルの放出調節製剤
BR122023020985A2 (pt) Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton
JP2017507995A5 (cg-RX-API-DMAC7.html)
AT501681A1 (de) Organische verbindungen
RU2019142507A (ru) Композиции, способы и системы для синтеза и применение визуализирующих средств
RU2013121788A (ru) Ингибиторы репликации вич
GB0814302D0 (en) Compounds and methods
WO2011160136A3 (en) Progesterone containing oral dosage forms and related methods
JP2015516418A5 (cg-RX-API-DMAC7.html)
JP2005523295A5 (cg-RX-API-DMAC7.html)
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
AR072858A1 (es) Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden
RU2014101261A (ru) Системы, способы и составы для лечения рака
ES3028429T3 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
JP2014521641A5 (cg-RX-API-DMAC7.html)
RU2017144574A (ru) Пероральная композиция целекоксиба для лечения боли
WO2003000290A1 (en) Antitumor agents
US20140100283A1 (en) Method to Increase Absorption and Bioavailability of Oral Glutathione
US10874741B2 (en) Compound to treat Sjogren's syndrome

Legal Events

Date Code Title Description
FC Application refused